Introduction {#s1}
============

The minimally invasive nature of transcatheter aortic valve replacement (TAVR) has made this procedure an attractive option for patient with symptomatic aortic stenosis with elevated surgical risk. Many factors increase the risk associated with surgical aortic valve replacement (SAVR) including porcelain aorta, prior sternotomy, prior chest irradiation, severe chest deformity, medical frailty, significant lung disease, and cirrhosis. But perhaps the strongest contraindication to SAVR is a history of coronary artery bypass graft (CABG) surgery. Previous studies have shown that cardiac reoperation is associated with an increase in perioperative myocardial infarctions, low-output heart failure, and death \[[@R01]\]. CABG is particularly high risk secondary to iatrogenic changes in anatomy such as a left internal mammary artery that crosses the midline.

Multiple studies have shown TAVR to be a superior option in high or intermediate risk surgical candidates \[[@R02], [@R03]\]. However there is conflicting evidence in the post-CABG population in regard to TAVR outcomes. For instance, Greason et al found that in comparison to SAVR, TAVR was associated with a nonstatistical trend toward greater all-cause mortality and a significant increase rehospitalization. In this study, TAVR was associated with a 36.1% death rate at 2 years \[[@R04]\]. On the other hand, studies by Nguyen et al and others have shown similar to improved outcomes with TAVR in this specific population \[[@R05], [@R06]\].

There is however a paucity of data on how patients with a history of prior CABG compare to other TAVR patients in terms of periprocedural and long-term outcomes. Historically, patients with history of CABG have increased mortality following major vascular procedures \[[@R07]\]. There may be clinically significant differences in procedural complications and clinical consequences that may be avoidable and potentially intervenable in the periprocedural and postprocedural period.

Furthermore, the published research on the outcomes and safety TAVR in patients with a history of CABG has all been from larger urban medical centers. These studies were conducted mainly at large volume centers which traditionally have more experience and better surgical outcomes for these advanced procedures. It is vital that the safety of TAVR in his particular patient population be also established in smaller, more rural surgical center as well. Our objective in this study was to both further establish the safety and acceptability of TAVR in patients with a history of CABG and demonstrate that post-TAVR outcomes from a smaller surgical center are comparable to the outcomes from urban medical centers.

Methods {#s2}
=======

A single institution retrospective cohort study was conducted. We performed a retrospective chart review of 337 consecutive patients who underwent TAVR at Sanford Health in Fargo, ND from August 10, 2012 to November 15, 2016 for severe aortic stenosis, defined as an aortic valve area less than 1 cm^2^. The last date of data acquisition was January 4, 2017. The entire cohort was divided in two groups where the patients with a history of CABG were placed in one cohort and all other patients were designated as controls. Primary outcomes were overall survival at 1 month, 6 months, 1 year, and 2 years post-TAVR. Secondary outcomes were procedural complications, post-TAVR permanent pacemaker (PPM) implantation, major adverse cardiovascular and cerebrovascular events (MACCE) defined as death from any cause, myocardial infarction, rehospitalization, or stroke, cardiovascular mortality, myocardial infarction, stroke/transient ischemic attack (TIA), heart failure exacerbation, or rehospitalization for any reason in defined time periods. Preprocedural, 24 h postprocedural, and 1 year postprocedural echocardiographic data were also compared. The clinical outcomes were assessed in accordance with the standardized endpoint definitions for TAVR of the Valve Academic Research Consortium-2 \[[@R08]\]. Heart failure exacerbation was defined as a gradual or rapid change in heart failure signs and symptoms resulting in a need for a change in therapy or hospitalization.

Informed consent was not required for inclusion in our retrospective study due to the nature of the study, and the absence of any direct interventions. This study protocol received dual IRB approval from the University of North Dakota IRB and from the Sanford Health IRB. The Fisher's exact test was performed to determine statistical significance of categorical data and *t*-test or Wilcoxon two-sample test were used to determine the statistical significance continuous variables. All P-values were two-sided, and P-values \< 0.05 were considered significant.

Results {#s3}
=======

A total of 96 of the 337 patients reviewed had a history of CABG prior to TAVR. Baseline characteristics for both groups are given in [Table 1](#T1){ref-type="table"}. Several statistically significant differences were noted in sex, STS risk score, EuroSCORE, preprocedural coronary artery disease (CAD), preprocedural abdominal aortic aneurysm (AAA). There were also slight differences in the utilization of several cardiovascular pharmacological agents including aspirin, beta blockers, and statins. There was a high amount of significant comorbidities in both groups including a 73% prevalence of CAD in the entire cohort. Mean age of the entire cohort was 79.3 years of age. Procedural characteristics for both groups are given in [Table 2](#T2){ref-type="table"}. There was no statistical differences in the specific type of valve used, however there was small, but statistical significantly difference in mean valve size. Pre- and postprocedural echocardiographic data are given in [Table 3](#T3){ref-type="table"}. Differences in valve area, peak aortic velocity, peak and mean aortic gradient, and ejection fraction were noted at baseline. Patients with a history of CABG had a lower mean ejection fraction, but slight less aortic valve obstruction than controls. The baseline difference in ejection was sustained directly following the procedure, and patients with prior CABG had less of ejection fraction improvement at 24 h post-TAVR. The difference in ejection fraction at 1 year following the procedure was not significant.

###### Baseline Characteristics

                                                              CABG (96)      No CABG (241)   P-value
  ----------------------------------------------------------- -------------- --------------- ----------
  Age                                                         78.6 (7.99)    79.6 (9.16)     0.3679
  Male sex                                                    74 (77)        112 (46)        \< 0.001
  BMI                                                         30.75 (5.84)   30.35 (6.38)    0.5963
  Caucasian race                                              95 (99)        239 (99)        1.000
  EuroSCORE (%)                                               12.89 (7.17)   6.92 (5.11)     \< 0.001
  STS risk score (%)                                          8.10 (4.77)    6.32 (3.69)     \< 0.001
  Preprocedural HTN                                           86 (90)        210 (87)        0.585
  Preprocedural CAD                                           96 (100)       151 (63)        \< 0.001
  Baseline ejection fraction \< 40%                           16 (17)        30 (12)         0.379
  Preprocedural NYHA Class III or IV symptoms                 44 (46)        105 (44)        0.717
  Preprocedural DM                                            40 (42)        80 (33)         0.166
  Prior stroke/TIA                                            13 (14)        25 (10)         0.446
  Preprocedural atrial fibrillation                           33 (34)        70 (29)         0.360
  Preprocedural serum creatinine (mg/dL)                      1.20 (0.36)    1.28 (0.98)     0.414
  Preprocedural eGFR \< 60 mL/min                             46 (48)        116 (48)        1.000
  Preprocedural PAD                                           33 (34)        58 (24)         0.058
  Preprocedural AAA                                           17 (18)        19 (8)          \< 0.001
  Preprocedural carotid artery stenosis \> 50% or prior CEA   34 (35)        58 (24)         0.042
  Prior PCI                                                   37 (39)        87 (36)         0.708
  Prior permanent pacemaker                                   14 (15)        26 (11)         0.353
  Prior aortic valvuloplasty                                  14 (15)        44 (18)         0.522
  Aspirin                                                     84 (88)        174 (72)        0.003
  ADP receptor inhibitor                                      30 (31)        77 (32)         1.000
  Beta blocker                                                85 (88)        163 (68)        \< 0.001
  HMG-CoA reductase inhibitor                                 86 (90)        154 (64)        \< 0.001
  Any anticoagulant                                           24 (25)        60 (25)         1.000

Values are mean (standard deviation) or n (%).

###### Procedural Characteristics

                                 CABG (n = 96)   No CABG (n = 241)   P-value
  ------------------------------ --------------- ------------------- ---------
  Approach                                                           
    Transfermoral                78 (81)         195 (81)            1.000
    Transapical                  16 (17)         34 (14)             0.611
    Transaortic                  1 (1)           6 (2)               0.678
    Trans-subclavian             0 (0)           6 (2)               0.189
    Transcaval                   1 (1)           0 (0)               0.285
  Mean LOS after TAVR (days)     4.1 (5.04)      5.1 (7.91)          0.276
  Valve type                                                         
    First generation Sapien      25 (26)         67 (28)             0.788
    Sapien XT                    14 (15)         37 (15)             1.000
    Sapien S3                    35 (36)         78 (32)             0.523
    First generation CoreValve   19 (20)         51 (21)             0.882
    CoreValve Evolute            3 (3)           8 (3)               1.000
    Mean valve size (mm)         26.4 (2.58)     25.7 (2.69)         0.0498

Values are mean (standard deviation) or n (%).

###### Echocardiographic Data

                                                         CABG            No CABG         P-value
  ------------------------------------------------------ --------------- --------------- ----------
  Preprocedural aortic valve area (VTI) (cm^2^)          0.918 (0.300)   0.820 (0.227)   0.002
  Preprocedural peak aortic velocity (cm/s)              395.1 (67.2)    426.2 (58.1)    \< 0.001
  Preprocedural peak aortic gradient (mm Hg)             64.2 (20.2)     74.3 (19.5)     \< 0.001
  Preprocedural mean aortic gradient (mm Hg)             40.9 (12.8)     46.7 (12.1)     \< 0.001
  Preprocedural ejection fraction (%)                    55.1 (13.2)     58.7 (12.2)     0.017
  Pre-procedural stroke volume (mL)                      86.8 (19.3)     85.0 (21.2)     0.536
  Preprocedural interventricular septum thickness (mm)   12.5 (2.5)      12.6 (2.5)      1.000
  Preprocedural moderate aortic regurgitation (%)        22              19              0.877
  Preprocedural severe aortic regurgitation (%)          4               4               1.000
  Preprocedural moderate mitral regurgitation (%)        26              21              0.309
  Preprocedural severe mitral regurgitation (%)          4               3               0.747
  24 h post-TAVR aortic valve area (VTI) (cm^2^)         2.25 (0.709)    2.17 (0.630)    0.324
  24 h post-TAVR peak aortic velocity (cm/s)             221.9 (65.7)    221.8 (51.4)    0.990
  24 h post-TAVR peak aortic gradient (mm Hg)            21.1 (14.1)     20.8 (9.9)      0.831
  24 h post-TAVR mean aortic gradient (mm Hg)            12.9 (8.8)      12.2 (5.9)      0.432
  24 h post-TAVR ejection fraction (%)                   57.9 (12.7)     62.7 (12.4)     0.002
  24 h post-TAVR stroke volume (mL)                      96.8 (27.4)     93.0 (27.9)     0.289
  24 h post-TAVR moderate aortic regurgitation (%)       5               5               1.000
  24 h post-TAVR moderate mitral regurgitation (%)       13              9               0.423
  24 h post-TAVR severe mitral regurgitation (%)         3               2               0.412
  1 year post-TAVR aortic valve area (VTI) (cm^2^)       2.07 (0.686)    1.96 (0.556)    0.306
  1 year post-TAVR peak aortic velocity (cm/s)           225.7 (59.4)    218.2 (44.5)    0.397
  1 year post-TAVR peak aortic gradient (mm Hg)          22.0 (12.3)     20.0 (8.9)      0.284
  1 year post-TAVR mean aortic gradient (mm Hg)          12.2 (7.0)      11.6 (5.2)      0.530
  1 year post-TAVR ejection fraction (%)                 55.1 (13.5)     59.5 (12.6)     0.058
  1 year post-TAVR stroke volume (mL)                    96.7 (30.2)     91.5 (27.4)     0.320
  1 year post-TAVR moderate aortic regurgitation (%)     8               15              0.302
  1 year post-TAVR moderate mitral regurgitation (%)     10              13              0.791
  1 year post-TAVR severe mitral regurgitation (%)       2               8               0.272

Values are mean (standard deviation) or %.

Finally, the primary and secondary outcomes data for this study are given in [Table 4](#T4){ref-type="table"}. There was a nonsignificant trend towards improved overall survival in the CABG cohort. However, a history of prior CABG was associated with a statistically significant increase in need for post-TAVR PPM implantation. No other significant differences in study outcomes were noted between the two groups.

###### Primary and Secondary Outcomes

                                                                  CABG         No CABG        P-value
  --------------------------------------------------------------- ------------ -------------- ---------
  \% Survival \> 1 month                                          98 (94/96)   93 (225/241)   0.112
  \% Survival \> 6 month                                          94 (78/83)   87 (163/188)   0.094
  \% Survival \> 1 year                                           85 (58/68)   77 (119/154)   0.206
  \% Survival \> 2 year                                           70 (29/41)   57 (59/104)    0.135
  Periprocedural major vascular                                   6 (6)        10 (23)        0.394
  Periprocedural minor vascular                                   7 (7)        10 (23)        0.672
  Periprocedural blood transfusion                                5 (5)        11 (27)        0.102
  Post-TAVR PPM implantation                                      15 (14)      6 (14)         0.015
  Periprocedural increase in serum creatinine \> 1.5 × baseline   4 (4)        6 (15)         0.604
  In hospital                                                                                 
    CV mortality                                                  3 (3)        6 (15)         0.298
    Myocardial infarction                                         2 (2)        0 (0)          \<.001
    Stroke/TIA                                                    0 (0)        3 (8)          0.111
    HF exacerbation                                               14 (13)      24 (57)        0.052
  Discharge to 30 days                                                                        
    MACCE                                                         20 (19)      17 (38)        0.521
    CV mortality                                                  0 (0)        1 (0)          1.000
    Myocardial infraction                                         1 (1)        1 (3)          1.000
    Stroke/TIA                                                    0 (0)        1 (3)          0.558
    HF exacerbation                                               16 (15)      16 (36)        1.000
    Rehospitalization for any reason                              20 (19)      17 (37)        0.421
  30 days - 6 months                                                                          
    MACCE                                                         29 (23)      26 (44)        0.543
    CV mortality                                                  0 (0)        3 (5)          0.329
    Myocardial infraction                                         3 (2)        1 (2)          0.592
    Stroke/TIA                                                    0 (0)        3 (5)          0.329
    HF exacerbation                                               18 (14)      14 (24)        0.453
    Rehospitalization for any reason                              29 (23)      22 (37)        0.203
  6 months -1 year                                                                            
    MACCE                                                         33 (20)      29 (35)        0.607
    CV mortality                                                  3 (2)        2 (2)          0.602
    Myocardial infraction                                         2 (1)        3 (3)          1.000
    Stroke/TIA                                                    2 (1)        1 (1)          1.000
    HF exacerbation                                               17 (10)      21 (25)        0.554
    Rehospitalization for any reason                              30 (18)      27 (33)        0.728

Values are % (n). MACCE: major adverse cardiovascular and cerebrovascular events, defined as death from any cause, myocardial infarction, rehospitalization, and stroke.

Discussion {#s4}
==========

This study further characterizes the efficacy and safety of TAVR in patients with a history of severe aortic stenosis and prior CABG and gives evidence to suggest that outcomes from lower volume centers are equitable to the previous published multicenter studies. Furthermore, although this study does not directly compare TAVR outcomes to SAVR outcomes, this study helps dispel concerns about an excessive risk of increased overall mortality with TAVR after CABG and demonstrates clinically acceptable outcomes in this specific population.

Importantly, our study also establishes the clinical safety of a TAVR in patient with prior CABG. As previously noted, concerns about the safety of major vascular interventions after CABG were formerly warranted. However, we found no difference in overall survival between the two cohorts in this study and actually found a nonsignificant trend towards improved overall survival. This trend is remarkable given the larger risk surgical risk and increased burden of significant comorbidities at baseline. For instance, our prior CABG cohort did have a much larger proportion of male patient which has been associated with increased mortality after TAVR in some studies \[[@R9]\]. As evidence in lower surgical risk population evolves, comparisons between prospectively defined TAVR patient groups will become of increased clinical importance and define clinical indication for post-TAVR follow-up.

This study did find a significant increase in post-TAVR PPM implantation after TAVR in post-CABG patients. To our knowledge, this is the first study to document an increased risk in TAVR-associated PPM in a specific and non-electrophysiologically defined patient population. This risk could potentially be reduced by high valve positioning, which has been associated with lower risk of PPM \[[@R10]\]. Frequent electrocardiogram (EKG) monitoring in immediate and short-term follow-up period in this specific patient population may be indicated.

The noninferiority of survival outcomes in the prior CABG cohort in our study despite higher EuroSCORE and STS risk scores suggests that traditional risk scores may not accurately reflex the true risk associated with TAVR. This has also been suggested in other previous published studies. For example, the work by Yamaoka and colleagues suggested that STS scores may overestimate the true mortality risk of TAVR \[[@R11]\]. On the other hand, a meta-analysis from 2014 suggested that both of these scoring algorithms underestimate the risk of TAVR \[[@R12]\]. Taken together, these studies and the findings of this study suggest that there needs to be a more personalized and academically more rigorous way of estimating the risk of TAVR in the periprocedural period. More studies on patients' specific factors like a history of prior CABG will advance the understanding of TAVR and help define which factors are true determinants of preoperative risk.

Finally, our study does have some limitations including its retrospective design, single center experiences, and variability in the length of post-TAVR follow-up. Unsurprisingly, there are some statistically significant differences in baseline characteristics, however these differences are of little clinical significance and likely do not impact this study's conclusions. Previous studies have shown that male sex may be a negative prognostic marker post-TAVR, however the effect size of this appears to be small \[[@R9], [@R13]\]. A history of CAD regardless of severity prior to TAVR has not been associated with worse outcomes after TAVR \[[@R14]\]. The impact of HMG Co-A reductase inhibitors on TAVR outcomes has been studied only retrospectively to date and there is an overall paucity of data, including no data from large databases \[[@R15]\]. Additionally, we are not aware any data that would suggest a difference in outcomes in patients with a history of AAA or the absence of beta blocker or aspirin use prior to TAVR.

Conclusions {#s4a}
-----------

In this single center study of patients undergoing TAVR, no difference in overall survival was seen in patients with a prior history of CABG versus a cohort of patient without a history of CABG. A history of prior CABG was associated with an increased risk of post-TAVR PPM implantation. This study affirms the efficacy and safety of TAVR in prior CABG patients in comparison to other TAVR patients at lower predicted surgical risk. Our study also confirms the safety of TAVR in this specific population in lower volume centers.
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